Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Related Citations for PubMed (Select 18419393)

1.

Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.

Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S170-7. doi: 10.1086/522161. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

2.

The safety profile of varicella vaccine: a 10-year review.

Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. Review.

3.

Postlicensure safety surveillance for varicella vaccine.

Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR.

JAMA. 2000 Sep 13;284(10):1271-9. Erratum in: JAMA 2000 Dec 27;284(24):3129.

PMID:
10979114
4.

Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J.

Vaccine. 2010 Aug 16;28(36):5878-82. doi: 10.1016/j.vaccine.2010.06.056. Epub 2010 Jun 30.

PMID:
20600487
5.

Fatal varicella due to the vaccine-strain varicella-zoster virus.

Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, Bialek SR, Marin M.

Hum Vaccin Immunother. 2014;10(1):146-9. doi: 10.4161/hv.26200. Epub 2013 Aug 27.

6.

The postmarketing safety profile of varicella vaccine.

Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA.

Vaccine. 2000 Nov 22;19(7-8):916-23.

PMID:
11115716
7.

Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.

Sauerbrei A, Eichhorn U, Gawellek S, Egerer R, Schacke M, Wutzler P.

J Med Virol. 2003 Oct;71(2):313-9.

PMID:
12938208
9.
10.

Perspective on live varicella vaccine.

Gershon AA, Katz SL.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S242-5. doi: 10.1086/522151.

11.

Prevention strategies: experience of varicella vaccination programmes.

Patrick D.

Herpes. 2007 Sep;14 Suppl 2:48-51.

PMID:
17939897
12.

Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine.

Levin MJ, DeBiasi RL, Bostik V, Schmid DS.

J Infect Dis. 2008 Nov 15;198(10):1444-7. doi: 10.1086/592452.

13.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

14.

Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old.

Ota K, Kim V, Lavi S, Ford-Jones EL, Tipples G, Scolnik D, Tellier R.

Pediatr Infect Dis J. 2008 Sep;27(9):847-8. doi: 10.1097/INF.0b013e318170af75.

PMID:
18664930
15.

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Gershon AA, Gershon MD.

Clin Microbiol Rev. 2013 Oct;26(4):728-43. doi: 10.1128/CMR.00052-13. Review.

16.

Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.

Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M.

J Infect Dis. 2013 Dec 1;208(11):1859-68. doi: 10.1093/infdis/jit405. Epub 2013 Aug 6.

17.

The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.

Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S224-7. doi: 10.1086/522162. Review.

18.

Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, G├╝ris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40.

19.

Live attenuated varicella vaccine.

Arvin AM, Gershon AA.

Annu Rev Microbiol. 1996;50:59-100. Review.

PMID:
8905076
20.

The impact of varicella vaccination in the United States.

Hambleton S, Gershon AA.

Semin Pediatr Infect Dis. 2005 Jan;16(1):38-43. Review.

PMID:
15685148
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk